Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone
Abstract Background The patients with multisystem and risk organ involvement Langerhans cell histiocytosis (MS-RO + LCH) have poor prognosis. The patients with MS-LCH who failed front-line therapy have a high mortality rate and the standard salvage treatment has not been established. The combination...
Saved in:
Main Authors: | Wenqian Wang (Author), Jian Ge (Author), Honghao Ma (Author), Hongyun Lian (Author), Lei Cui (Author), Yunze Zhao (Author), Zhigang Li (Author), Tianyou Wang (Author), Rui Zhang (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2024-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical features and treatment outcomes of liver involvement in paediatric Langerhans cell histiocytosis
by: Xinshun Ge, et al.
Published: (2024) -
Outcomes of salvage therapy for relapsed / refractory Langerhans cell Histiocytosis: Experience from a tertiary care centre
by: Shivam Sharma, et al.
Published: (2024) -
Use of BRAF inhibitor (Vemurafenib) in a child with Refractory Langerhans cell histiocytosis
by: Anil Sharma, et al.
Published: (2017) -
Langerhans cell histiocytosis of the rib
by: Zhenting Tang, et al.
Published: (2021) -
Langerhans cell histiocytosis
by: D R Aruna, et al.
Published: (2011)